What Treatment Should We Use If Drugs Fail for OAB; and, What Really Works After Drugs?

被引:7
|
作者
Bosch, J. L. H. R. [1 ]
Kelleher, C. [2 ]
van Kerrebroeck, P. E. V. [3 ]
Schurch, B. [4 ]
机构
[1] Univ Med Ctr Utrecht, Dept Urol, NL-3508 GA Utrecht, Netherlands
[2] Guys & St Thomas NHS Fdn Trust, Dept Obstet & Gynaecol, London, England
[3] Maastricht Univ, Med Ctr, Dept Urol, Maastricht, Netherlands
[4] Univ Hosp Balgrist, Dept Neurourol, Zurich, Switzerland
关键词
drug treatment; neuromodulation; overactive bladder; urinary incontinence;
D O I
10.1002/nau.20906
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aims: To determine (using structured brain storm sessions), which treatments should be used if drugs fail for OAB and to determine priority research questions in relation to this issue. Methods: A frame work for discussion was prepared by the chairman of the session; this included a brief summary of the currently existing evidence. Several experts had been asked to prepare a presention of their personal treatment algorithm and to identify the [lack of] evidence for such an algorithm. These presentations were summarized by the chairman. Next, this summary was discussed with a large group of experts and opinion leaders and audio-recorded. The proceedings of this process are the basis for this manuscript. Results: The structured sessions resulted in detailed statements about: possible reasons for failure of conservative treatment:, the evaluation of outcomes of RCT's, the use of botulinum toxin A in refractory OAB patients, the relative place of neuromodulation or sacral nerve stimulation and botulinum toxin A in the treatment of refractory OAB. Conclusions: A list of 10 unanswered questions and research topics was compiled. Additionally, 5 top priority research topics were identified. Neurourol. Urodynam. 29:658-661, 2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:658 / 661
页数:4
相关论文
共 50 条
  • [31] WHY DRUGS FAIL? WHAT COULD HAVE BEEN DONE?
    Miller, K. L.
    Stevens, C. A.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A262 - A263
  • [32] WHAT DO WE PAY FOR COMPOUNDED DRUGS?
    Lin, T.
    Tran, D. M.
    Shoair, O. A.
    Huang, W.
    Cao, V
    Wilson, L.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A818 - A818
  • [33] Interactions of marihuana and THC with other drugs -: What we don't, but should, know
    Hollister, LE
    [J]. MARIHUANA AND MEDICINE, 1999, : 273 - 277
  • [34] Designing drugs that overcome antibacterial resistance: where do we stand and what should we do?
    Penchovsky, Robert
    Traykovska, Martina
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (06) : 631 - 650
  • [35] How advertising works: What do we really know?
    Vakratsas, D
    Ambler, T
    [J]. JOURNAL OF MARKETING, 1999, 63 (01) : 26 - 43
  • [36] WHAT DRUGS SHOULD BE USED IN THE TREATMENT OF RHEUMATOID-ARTHRITIS AND IN WHICH SEQUENCE
    SCHMIDT, KL
    [J]. MEDIZINISCHE WELT, 1987, 38 (48): : 1588 - 1589
  • [37] Diverticular colovesical fistula: What should we really be doing?
    N. L. Bertelson
    H. Abcarian
    K. A. Kalkbrenner
    J. Blumetti
    J. L. Harrison
    V. Chaudhry
    T. M. Young-Fadok
    [J]. Techniques in Coloproctology, 2018, 22 : 31 - 36
  • [38] Diverticular colovesical fistula: What should we really be doing?
    Bertelson, N. L.
    Abcarian, H.
    Kalkbrenner, K. A.
    Blumetti, J.
    Harrison, J. L.
    Chaudhry, V.
    Young-Fadok, T. M.
    [J]. TECHNIQUES IN COLOPROCTOLOGY, 2018, 22 (01) : 31 - 36
  • [39] Injury prevention activities: What should we really be doing?
    Graham, Colin A.
    [J]. INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2007, 38 (05): : 548 - 549
  • [40] Drugs and pregnancy: what should know the community pharmacist
    Bellet, Florelle
    Joannet, Bettina
    Marsille, Fakhria
    Mounier, Genevieve
    Guy, Claire
    Beyens, Marie-Noelle
    [J]. ACTUALITES PHARMACEUTIQUES, 2013, 52 (529): : 18 - 25